Reuters logo
BRIEF-Ampliphi Biosciences says had cash and cash equivalents of $2.2 mln as of March 31
2017年5月1日 / 上午11点26分 / 7 个月前

BRIEF-Ampliphi Biosciences says had cash and cash equivalents of $2.2 mln as of March 31

May 1 (Reuters) - Ampliphi Biosciences Corp

* Ampliphi Biosciences Corp - Ampliphi had cash and cash equivalents of $2.2 million as of March 31, 2017

* Ampliphi Biosciences Corp - filed its Australian tax return and now expects receipt of a $1.8 million tax incentive payment early in Q3 of 2017

* Ampliphi Biosciences Corp - has made operational changes that are expected to reduce cash expenditures in 2017

* Ampliphi - expects to provide personalized phage therapies to patients suffering from multidrug-resistant infections who have failed prior therapies

* Ampliphi Biosciences - also seeking to advance chronic rhinosinusitis, preclinical cystic fibrosis programs through partnerships, non-dilutive funding Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below